


cryoport^o

SCIENCE. SUPPLY CHAIN. CERTAINTY.

cryoport^o
SCIENCE. SUPPLY CHAIN. CERTAINTY.



Forward Looking Statements


Statements in this presentation and statements made orally during this presentation are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as "believe," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "seek," "plan," "expect," "should," "would" or similar expressions are intended to identify forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties.

These forward-looking statements include, but are not limited to, statements concerning the potential benefit of Cryoport's acquisitions of CRYOPDP and MVE and the estimated or anticipated future business, performance and results of operations following the transaction. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, (1) risks and uncertainties associated with the effect of changing economic conditions, (6) trends in the products markets, (7) variations in Cryoport's cash flow, (8) market acceptance risks, (9) technical development risks and (10) other unforeseen risks. Cryoport's business could be affected by a number of other factors, including the risk factors listed from time to time in Cryoport's SEC reports including, but not limited to, Cryoport's 10-K for the year ended December 31, 2019, Cryoport's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and any subsequent filings with the SEC. Cryoport cautions you not to place undue reliance on the forward-looking statements contained in this presentation, which only speak as of the date hereof. Except as required by law, Cryoport disclaims any obligation, and does not undertake, to update or revise any forward-looking statements.

The offering to which this presentation relates will be made pursuant to an automatic shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (the "SEC") and automatically became effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC's website located at <http://www.sec.gov> or may be obtained from Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Jefferies, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; SVB Leerink, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525, ext. 6132 or by email at syndicate@svbleerink.com; or UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, by telephone at (888) 827-7275 or by email at ol-prospectus-request@ubs.com.

This presentation includes Adjusted EBITDA, a non-GAAP financial measure. Cryoport defines Adjusted EBITDA as net income (loss), as adjusted for depreciation and amortization expense, interest expense, net, stock-based compensation expense, income taxes and acquisition costs. Adjusted EBITDA is in addition to and not a substitute for or superior to measures of financial performance prepared in accordance with GAAP and should not be considered as an alternative to revenue, net income, operating income or any other performance measures derived in accordance with GAAP. A reconciliation of Adjusted EBITDA to its most directly comparable GAAP counterpart, net income (loss), included in this presentation.

Cryoport believes this non-GAAP measure provides a useful measure of the Company's operating results, a meaningful comparison with historical results and with the results of other companies, and insight into the Company's ongoing operating performance. Further, management and the Board of Directors utilize this non-GAAP financial measure to gain a better understanding of the Company's comparative operating performance from period-to-period and as a basis for planning and forecasting future periods. However, there are a number of limitations related to the use of these or other non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance and therefor Cryoport's measure of Adjusted EBITDA may not be directly comparable to similarly titled measures of other companies.



Cryoport – A Trusted Partner to Life Sciences Companies

- Life sciences company focused on providing mission critical, proprietary temperature-controlled supply chain solutions
- Capabilities include core competencies to ship, store and deliver biologics in a cryogenic or temperature-controlled state such as:
 - CAR-T and allogeneic therapies
 - Human and animal reproductive materials
 - Vaccines
- Majority of cell therapies need to be shipped at cryogenic temperatures (-196°C)
- A leading global manufacturer of cryogenic equipment and supplies
- Third largest healthcare specialty logistics provider by revenue

cryoport[○]
systems
a cryoport company

CRYOPDP[○]
a cryoport company

cryoport[○]
SCIENCE. SUPPLY CHAIN. CERTAINTY.
*Leading provider of
temperature-
controlled supply
chain solutions and
products to the life
sciences industry*

MVE Biological Solutions[○]
a cryoport company

CRYOGENE[○]
a cryoport company

Cryoport, Inc. (CYRX) operates as a operating holding company with a family of businesses that have separate responsibilities but collectively provide synergistic solutions to the life sciences industry


cryoport[○]
SCIENCE. SUPPLY CHAIN. CERTAINTY.

A Global Leader of Temperature-Controlled Supply Chain Solutions for the Life Sciences




528

Active **Cell & Gene Therapy**
Clinical Trials Supported



~45%

of all Phase III **Regenerative Medicine** Clinical Trials Supported



~31% / ~53%

Growth in Clinical Trials Supported ⁽¹⁾ Growth in Revenue ⁽¹⁾



\$47.7 – \$48.5MM

Q4 2020E Revenue



5

Commercial **Cell & Gene Therapies** Supported



265+

Active Global Clients



350,000+

Shipments



29

COVID-19 Vaccines /
Treatments Supported


The Industry's Most Trusted Provider of Temperature-Controlled Supply Chain Solutions for Temperature-Sensitive Life Sciences Industry

Notes:
1. '17 – '20 CAGR for Legacy Cryoport
All other data provided is year ended December 31, 2020, unless otherwise noted

Attractive High-Growth Regenerative Medicine Market Driving Expected Demand


Therapies Approved by Scenario

new therapies approved by FDA



Patients Treated per Year in Trials of Commercially Approved Therapies


of patients treated in-year with C> therapies (000's)




Source: Leading third party consulting firm analysis

Notes: Some therapies, such as those focused on treating Hepatitis A and B, will drive higher patient populations; In order to avoid predicting success of individual therapies, we have assumed a standard number of treatable patients per therapy based on average incidents currently in trials. This rate assumes that the total patient population treatable by each therapy does not wholly "replenish" each year, given rare nature of many disease that C & GT targets

Cryoport Grows with Dynamic and Expanding TAM



Cell & Gene Therapy Market




The acquisitions of CRYOPDP and MVE Biological Solutions expand Cryoport's addressable market and provide our customers with end-to-end support across the Cell and Gene Therapy value chain.



Cryoport Systems' Differentiators

- **Fully Integrated** System, Processes and Equipment
- Life Sciences Industry's **Most Advanced Informatics Platform**
- **24/7/365 Personnel**
- Full **Chain of Compliance**®



Cryoport Express® Shippers are Validated for Safe, Effective and Efficient Transport

Cryoport Express® Shippers – Ensures the Integrity of Shipped Materials

Cryoport Express® Shippers are designed to be non-hazardous and capable of maintaining temperatures of under -150 C for up to 10 days under dynamic conditions



Dewar



Secondary Packaging:
Blood Cassette Rack and
Safepak® XL



Smartpak™
Condition Monitoring
System



Sliderite® mobile pallet to
assure shipper remains in
the upright position

Cryoportal® and Smartpak II® Systems – Near real-time Monitoring

Cryoport and its customers can monitor and track every shipment and key statistics, including Chain of Compliance®



Minimizing Risk and Maximizing Success

Chain of Custody

Traceability of the Custody of each Client's or Patient's Therapy

Chain of Condition

Traceability of the Condition of each Client's or Patient's Therapy

Chain of Identity

Traceability of the Identity of each Client's or Patient's Therapy




CHAIN OF COMPLIANCE®

Traceability of the Equipment and Processes Supporting each Client's or Patient's Therapy


Clinical Trial Funnel to Commercial Biopharma Revenue

69 Phase III Clinical Trials Supported by Cryoport, 5 Commercial Therapies




5 Commercial Therapies:

- ✓ KYMRIA[®] by Novartis
- ✓ YESCARTA[®] by Gilead/Kite
- ✓ TECARTUS[™] by Gilead/Kite
- ✓ ZYNTEGLO[®] by bluebird bio
- ✓ LIMBEMELDY[™] by Orchard



Cryoport's History of Amplifying Strength across the Life Sciences Landscape



With the company's recent acquisitions, Cryoport provides a more integrated, end-to-end supply chain solution set to cell and gene therapy clients as well as the broader life sciences industry

CRYOPDP – Uniquely Positioned Global Temperature-Controlled Supply Chain Network to Support the Life Sciences Industry

CRYOPDP is the **third largest** specialty global logistics player ⁽¹⁾ providing customized and tailor-made turnkey global transport solutions for high value, time critical and temperature sensitive pharmaceuticals.

**Headquarters: Paris, France**

**230 employees in 12 countries**


**Serving 150 countries**

**25 Years of Service**



Notes:
1. Measured by revenue
2. Revenue for the nine months ended September 30, 2020

Attractive Financial Profile



Expected to be **immediately accretive**



Global Scale of a Unified Cryoport and CRYOPDP Network



 Cryoport Locations

 CRYOPDP Locations





 MVE Biological Solutions Locations



MVE Biological Solutions Overview

MVE Biological Solutions is a **leading manufacturer of cryogenic life sciences equipment**, providing freezers, dewars and related equipment used for storage and transportation

- Three primary locations
 - Ball Ground, GA
 - New Prague, MN
 - Chengdu, China




Note:

1. Revenue for the nine months ended September 30, 2020 as a stand-alone company

Attractive Financial Profile

Revenue


\$MM



Current Cell & Gene Therapy Pipeline Driving Revenue Growth




- **Seven** Cryoport supported Marketing Authorization Applications (MAA's) or Biologic License Applications (BLA's) were filed in 2020
- Anticipate up to **23** MAA or BLA submissions for Cryoport-supported products in 2021

Each of these therapies require comprehensive temperature-controlled supply chain services including logistics and bioservices support at scale




COVID-19 Support

Clinical Trials Supported by Cryoport

	18 trials
	6 trials
	5 trials
Total Clinical Trials	<div>As of 12/31/2020, Cryoport supported 29 separate clinical trials across our business units, <i>including a leading COVID-19 vaccine candidate</i></div> 29 trials


In Q3 2020, MVE Biological Solutions received several orders from government tenders and through our distribution network for storage systems that are destined for use in storing pandemic related materials.

Financial Overview




Compelling Revenue Profile

Q4 Revenue ⁽¹⁾



Fiscal Year Revenue ⁽¹⁾



Note:

1. Includes midpoint of revenue range for Q4 2020 and FY2020E

2019
 2020

Pro Forma Income Statement

Cryoport, Inc. and Subsidiaries Unaudited Pro Forma Condensed Combined Statements of Operations

Year Ended December 31, 2019

<i>in MM</i>	Cryoport	Pro Forma CRYOPDP	Pro Forma MVE	Pro Forma Combined
Revenues	33.9	47.4	81.9	163.2
Cost of revenues	16.6	28.9	43.4	88.9
Gross Margin	17.4	18.5	38.4	74.3
Operating costs and expenses:				
General and administrative	17.5	20.7	13.0	51.1
Sales and marketing	13.8	0.1	4.2	18.1
Engineering and development	3.7	--	1.9	5.6
Total operating costs and expenses	35.0	20.8	19.0	74.9
Income (loss) from operations	(17.7)	(2.3)	19.4	(0.6)
Other income (expense):				
Interest expense	(1.4)	(0.4)	--	(1.8)
Other income (expense), net	0.8	(0.1)	(0.1)	0.6
Total other expense, net	(0.6)	(0.5)	(0.1)	(1.2)
Income (loss) before provision for income taxes	(18.3)	(2.7)	19.3	(1.7)
Provision for income taxes	(.06)	(0.1)	(1.3)	(1.4)
Net income (loss)	(18.3)	(2.8)	18.0	(3.1)
Net earnings (loss) per share - basic and diluted	(0.55)			(0.09)
Weighted average common shares outstanding - basic and diluted	33.4		0.7	34.1


Cryoport, Inc. and Subsidiaries Unaudited Pro Forma Condensed Combined Statements of Operations

Nine-Month Ended September 30, 2020


<i>in MM</i>	Cryoport	Pro Forma CRYOPDP	Pro Forma MVE	Pro Forma Combined
Revenues	30.3	35.5	58.0	123.8
Cost of revenues	13.9	22.5	30.7	67.1
Gross Margin	16.4	12.9	27.3	56.7
Operating costs and expenses:				
General and administrative	20.6	16.3	2.2	39.1
Sales and marketing	10.1	0.1	2.5	12.7
Engineering and development	6.0	--	1.2	7.1
Total operating costs and expenses	36.6	16.4	5.9	58.9
Income (loss) from operations	(20.2)	(3.5)	21.4	(2.2)
Other income (expense):				
Interest expense	(1.5)	(1.9)	--	(3.4)
Other income (expense), net	0.5	--	0.1	0.6
Income (loss) before provision for income taxes	(21.1)	(5.4)	21.5	(5.0)
Provision for income taxes	(0.1)	(1.1)	(0.9)	(2.1)
Net income (loss)	(21.2)	(6.5)	20.6	(7.0)
Net earnings (loss) per share - basic and diluted	(0.55)			(0.2)
Weighted average common shares outstanding - basic and diluted	38.2		0.7	38.9

Immediately Accretive Pro Forma Adjusted EBITDA Profile

9 Month Trailing Adj. EBITDA (as of 9/30/20) ⁽¹⁾



FY 2019 Adj. EBITDA ⁽¹⁾




Expanding Tools and Solutions for the Life Sciences



Synergies – Cryoport Family of Companies – Separate Responsibility – Intercompany agreements and sales incentives

Summary

- | End-to-end solutions platform offering fully integrated temperature controlled supply chain solutions for the life sciences
- | Well positioned to take advantage of the growing needs in the cell & gene therapy market
- | A market leader with long-term client agreements and diverse client base
- | Leading, proprietary solutions: Cryoport® Logistics Management Platform, Smartpak II® Condition Monitoring System technology and Cryoport Express® shipper fleet
- | A global leader in cryogenic manufacturing
- | Third largest healthcare focused specialty logistics provider by revenue
- | Operating holding company platform in place for future growth
- | Financial partnership with Blackstone
- | Strong revenue performance



Management



Jerrell Shelton,
Chief Executive
Officer, Cryoport Inc.
and MVE
Biological Solutions



Robert Stefanovich,
Chief Financial
Officer, Cryoport Inc.



Thomas Heinzen,
Vice President -
Corporate
Development &
Investor Relations,
Cryoport Inc.



Kylie Crowe,
Vice President Global
Human Resources,
Cryoport Inc.



Mark W. Sawicki,
Ph.D., Chief Scientific
Office, Cryoport, Inc.,
Chief
Executive Officer,
Cryoport Systems




Marshal Griswold,
Chief Executive
Officer, CRYOGENE



Cedric Picaud,
Chief Executive
Officer, CRYOPDP



Buzz Bies,
Vice President and
General Manager/Chief
Commercial Officer,
MVE Biological
Solutions



Board of Directors



Jerrell Shelton,
Chairman of
the Board



Richard Berman,
Lead Director



Daniel M. Hancock



Robert Hariri,
PhD, MD




Ram Jagannath



Ramkumar
Mandalam, Ph.D.




Edward Zecchini




Science. Logistics. **Certainty.**

Thank you!



Supplementary Materials



Adjusted EBITDA Reconciliation

Unaudited Pro Forma Combined Adjusted EBITDA

Nine Months Ended September 30, 2020

<i>in MM</i>	Cryoport	CRYOPDP	MVE	Pro Forma Combined
GAAP net income (loss)	(21.2)	(6.5)	20.6	(7.1)
Non-GAAP adjustments to net loss:				
Depreciation and amortization expense	2.5	3.3	8.3	14.1
Interest expense, net	0.9	1.9	–	2.8
Stock-based compensation expense	6.4	–	0.2	6.6
Income taxes	0.1	1.0	0.9	2.0
Acquisition costs	7.4	1.8	(5.7)	3.5
Adjusted EBITDA	(4.0)	1.5	24.3	21.9

Unaudited Pro Forma Combined Adjusted EBITDA

Year Ended December 31, 2019

<i>in MM</i>	Cryoport	CRYOPDP	MVE	Pro Forma Combined
GAAP net income (loss)	(18.3)	(2.9)	18.0	(3.2)
Non-GAAP adjustments to net loss:				
Depreciation and amortization expense	2.4	3.8	11.9	18.1
Interest expense, net	1.4	0.4	–	1.8
Stock-based compensation expense	16.5	–	0.2	16.7
Income taxes	0.1	0.1	1.3	1.5
Adjusted EBITDA	2.0	1.4	31.4	34.9